By
From the * Unité Institut National de la Santé et de la Recherche Médicale 373, Institut Necker,
75730 Paris Cedex 15; and Department of Microbiology, Mount Sinai School of Medicine, New
York 10029
Establishment of antigen-specific tolerance among mature T cells has been a long debated, yet poorly understood issue. In this study we have used transgenic mice bearing a class II-restricted TCR specific for the hemmagglutinin of the influenza virus in order to test the behavior of CD4+ T cells upon exposure to antigen in different forms and doses. We first studied the fate of T cells expressing the transgenic TCR (6.5) in double transgenic mice where HA was expressed as a self antigen by hemapoietic cells. In these mice, we found some mature T cells in periphery that had escaped thymic deletion and that showed signs of activation but which were anergic. Mature CD4+6.5+ cells that were transferred into antigen-containing recipients went through an initial phase of expansion after which most cells were deleted and those remaining became unresponsive, as previously described for CD8+ cells. Inducing tolerance in CD4+6.5+ cells in situ in single transgenic mice proved a difficult task: classical protocols using single doses of soluble or deaggregated antigen as well as feeding antigen all failed to induce antigen-specific unresponsiveness. It was only after decreasing cell numbers by CD4 antibody treatment and by repeatedly reintroducing antigen thereafter that unresponsiveness of 6.5+ cells was achieved and maintained. In no case could we observe the appearance of antigen-specific T cells with a Th2 cytokine profile among the remaining cells and therefore conclude that deletion and anergy represent the major mechanisms of tolerance in our studies.
Self-nonself discrimination of the immune system is in
part due to an intrinsic difference in response to antigen
of immature versus mature T lymphocytes: self antigens that
are permanently present in the thymus delete immature T
cells by apoptosis while more mature T cells that have not
encountered their antigen during development can respond
in different ways that range from activation to effector function to the induction of non-responsiveness. The precise
mechanisms of unresponsiveness of mature T cells are still poorly understood but it has been shown that they may involve deletion (1, 2) or anergy (3). Other means in
which regulatory T cells can interfere with certain effector
functions have been proposed (6, 7) but here the evidence
is more indirect and the mechanisms that may involve regulation through cytokines need to be established in detail.
Induction of tolerance in mature T cells has for years
been attempted in many different ways also because of the
potential applications in organ-specific autoimmune diseases and transplantation. In these studies tolerance could
be achieved by injecting mice with high doses or low doses
of soluble antigen, for instance with deaggregated immunoglobulin (8, 9, for review see reference 10). In other
studies unresponsiveness was achieved by feeding antigen
and thus was named oral tolerance (11, for review see reference 12). Some of the proceedings gave however erratic results and there is still no procedure which reproducibly
induces specific tolerance to a variety of different antigens
that can be used to interfere with allergy, autoimmunity or
transplant rejection. This may be so because in the more
ancient experiments one could not study the mechanisms
of tolerance because it was difficult to follow the fate of the
antigen-specific cells after the attempted tolerization. More
recent studies that employed mice with transgenic T cell
receptors came to the conclusion that CD8+ T cells specific
for conventional antigen could either be deleted or anergized after a transient period of activation, depending on
the doses of antigen (13). Studies with CD4+ cells specific
for superantigens showed also that many CD4+ T cells underwent apoptotic cell death after activation by the superantigen (14). Since superantigens can bind to T cell receptors in a different way than conventional antigens without
direct contact between the TCR and superantigen binding
MHC molecules, it was not clear whether these results
could be extrapolated to CD4+ T cells recognizing conventional antigens. In mice expressing transgenic TCRs on
CD4+ T cells tolerization even with high doses of peptide
failed while it appeared that, upon adoptive transfer, smaller numbers of CD4+ T cells could be tolerized by peptide
(15), suggesting that the frequency of reactive T cells versus
the amount of antigen could be an important parameter in
the induction of certain forms of tolerance. Here we are reporting studies on TCR transgenic mice that express on
CD4+ but also on some CD8+ cells a receptor specific for
peptide 111-119 from influenza hemagglutinin (HA)1 presented by Ed MHC molecules (16). The transgenic receptor can be identified by a monoclonal anti-idiotypic antibody (6.5) and in the various transgenic mice the receptor
is expressed on ~7-10% of all CD4+ T cells in secondary
lymphoid organs. Although this frequency of antigen-specific cells is high in comparison to the frequency of T cells
specific for conventional non-MHC antigens (10 In these mice we analyzed various ways of antigen presentation that had the specific goal to tolerize CD4+ T
cells. We first studied tolerance under conditions in which the antigen was expressed by hemopoietic cells under control of the Ig- Mice.
TCR transgenic (6.5) mice already described (16) express a T cell receptor Antigen Administration Protocols.
The peptide (SVSSFERFEIFPK) was synthesized in the Basel Institute for Immunology.
The chimeric immunoglobulin HA-Ig contains the peptide 111119 of HA in the CDR3 region of the heavy chain as already described (17), and was prepared from the hybridoma supernatant
cultured in complete IMDM + 3% FCS previously run over a
protein G column (Fast Flow; Pharmacia LKB, Upsala, Sweden).
4), it is
about in the same range as the frequency of T cells responding to a foreign MHC haplotype.
promoter. Having obtained evidence that
under these conditions immature as well as mature CD4+
T cells can be tolerized, we attempted to define protocols
that employed soluble antigen in various forms to tolerize
mature CD4+ T cells in situ. Our results indicate that
CD4+ cells at a relatively high frequency are extremely difficult to tolerize in situ unless one employs strategies that
reduce their number and/or responsiveness before antigen
is introduced.
/
specific for peptide 111-119 from influenza hemmagglutinin presented by I-Ed. Phenotyping of offspring was done by FACS® staining of PBLs with the clonotypic
antibody. For the experimental protocols, heterozygous TCR
transgenic mice between 6 and 10 wk of age were used. Mice expressing hemagglutinin (HA+) have the HA transgene under control of the Ig
promoter and enhancer elements (Rolink A., not
published) and are on Balb/c background. Transgene expression
was determined by tail DNA PCR using HA primers. Balb/c
mice were obtained from IFFA CREDO (France).
Antibodies and FACS® Analysis. Hybridoma supernatants containing mAbs YTA3.1.2 (18) or 6.5 (anti-clonotypic antibody described before [15]) were purified by protein G (Fast Flow) affinity chromatography. 6.5 mAb was labeled using fluorescein succinyl ester (FLUOS) (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's instructions.
The following mAbs were used: FLUOS-labeled 6.5 mAb, anti CD8-red613 (GIBCO BRL, Gaithersburg, MD), anti-CD4PE (Becton Dickinson and Co., Mountain View, CA), biotin-conjugated anti-CD69 (PharMingen, San Diego, CA), biotin-conjugated anti-CD25 (PharMingen), biotin-conjugated anti-CD45RB (PharMingen), anti-CD62L (Mel 14, kind gift of F. Lepault), SA-PE (Southern Biotechnology Associates Inc., Birmingham, AL) and mouse anti-ratT Cell Proliferation and Cytokine Assays.
All in vitro assays were
performed in complete IMDM (-mercaptoethanol [5 × 10
5M]
penicillin [100 UI/ml]) supplemented with 10% FCS. Responder cells were isolated from the spleen and lymph nodes and depleted of B cells with the help of a sheep anti-mouse IgG (H+L) (Biosys, France) pre-coated on a petri dish at 10 µg/ml. T cells (2 × 105/
well) were then cultured with 5 × 105 irradiated (2,200 rads)
Balb/c splenocytes in the presence of 10 µg/ml, 1 µg/ml of peptide, coated 6.5 mAb (100 µg/ml), or medium alone. Exogenous
IL2 was added in some cases, at 30 UI/ml. 3H-incorporation was
measured over the last 18 h of a 66 h culture. Proliferation assays
were done for both spleen T cells and lymph node T cells and
since they gave similar results, only the former are shown. The
supernatant of a 66 h culture in the same conditions as for the
proliferation but containing 4 × 105 T spleen cells, was collected
and used for ELISA assay. The standards used permitted the detection in the supernatant of a minimum concentration of 150 pg/ml for IL4 and of 600 pg/ml for IFN-
. The antibodies used
were mAb AN-18.17 and biotin-conjugated R4-6A2 for IFN-
(ATCC HB-170), and 11B11 and biotin-conjugated BVD6-24G2
for IL4 (PharMingen). Horseradish peroxidase streptavidin (VECTOR Laboratories, Inc. Burlingame, CA) activity was revealed
by O-phenylenediamine dihydrochloride substrate (Sigma Chem.
Co.). Plates were read at 490 nm.
Transfer Experiments.
For the transfer of 6.5+ cells into HA+
transgenic recipients, lymph node cells from 6.5+/+RAG2/
mice were washed and resuspended in serum-free medium. 2.5 × 106 cells were injected into previously irradiated (500 rads) HA+
transgenic mice or HA
littermates. Recipients were killed and
analyzed 4, 8, 14, and 30 d after the transfer.
We first analyzed the fate of class II restricted cells in double transgenic mice where the antigen
would be constantly present at relatively high concentrations both in the thymus and in the periphery. For that
purpose, 6.5+ TCR transgenic mice were crossed to mice
transgenic for the HA gene under control of the immunoglobulin promoter. In the latter mice the antigen is expressed on hemopoietic cells and their spleen cells stimulate
a good response of unprimed T cells bearing the transgenic
TCR. In double transgenic mice (HA+6.5+), the absolute
number of thymocytes was about half that of HA
6.5+ littermates and, as shown in Fig. 1, the percentage of 6.5+
thymocytes among the CD4+CD8
and CD4
CD8+ subpopulations was drastically decreased. Note that in peripheral lymphoid tissue 6.5+ cells express less of the transgenic
receptor than thymocytes. This is in part due to the fact
that the peripheral T cells in these mice express in general
slightly lower TCR levels as judged by staining with the
TCR-
antibodies and analysis of RAG
/
6.5+ mice and
in part due to the fact that 6.5+ cells in the transgenic mice
express endogenous TCR-
chains (not shown). The percentages of double-negative, double-positive, and singlepositive thymocytes were not very different from that of
HA transgene negative littermates in part because other receptors generated by endogenous TCR
rearrangements
were selected. Likewise, the absolute number of peripheral
T cells was not greatly affected in HA+6.5+ mice and the
percentage of B and T cells in the spleen was similar to that
observed in 6.5+HA
littermates (data not shown). Surprisingly, however, 6.5+ cells could be detected in the periphery of the double transgenic mice and the frequency of
splenic 6.5+ cells was comparable to that of 6.5+HA
mice
(Fig. 1). There was no evidence for TCR or coreceptor
downregulation among peripheral 6.5+ cells from double
transgenic mice that had escaped deletion, but these cells differed from T cells from 6.5+HA
mice in that they had upregulated CD69 and downregulated CD62-L and CD45RB
levels (not shown). When splenic or lymph node T cells from the double transgenic mice were stimulated in vitro
either with antigen at different concentrations or with the
clonotypic antibody, the 6.5+ cells were unresponsive unlike those from 6.5+HA
mice which proliferated well
without prior immunization (Fig. 2, A and B). There was no
response when cells from normal, non-transgenic BALB/c
mice were stimulated either by antigen or the clonotypic antibody indicating that 6.5+ cells were essential for a proliferative response as well as cytokine production (see below). Addition of IL2 did not restore the response. These
data demonstrate that tolerance in class II restricted cells
can be induced by an antigen expressed in hemopoietic cells and that the mechanisms may involve deletion of immature cells as well as anergy of peripheral lymphocytes.
The anergy may have in fact been induced after thymic
emigration of the 6.5+ cells since at birth we cannot detect
in the thymus HA that can stimulate 6.5+ cells in vitro (not
shown).
CD4+ Cells Can Be Rendered Tolerant upon Transfer into Antigen-bearing Recipients.
We next addressed the question
whether mature naive CD4+ cells, when exposed to high
doses of antigen, would follow the same fate as previously
described for CD8+ cells (2, 13) . For this purpose, lymph
node cells from RAG/
6.5+/+ mice were injected i.v.
into x-irradiated HA+ mice or HA negative littermates and
recipients were analyzed at different time points after transfer. As can be seen in Fig. 3, during the first 4 d 6.5+ cells
expanded vigorously upon transfer into antigen-positive recipients and cell numbers declined thereafter. In contrast, when 6.5+ cells were transferred into HA
recipients, there
was no significant expansion of these cells during the period of observation though about five percent of the injected cells could be recovered from these recipients. 6.5+
cells recovered at day 4 after transfer into HA-containing
recipients were capable of responding to antigenic stimulation in vitro, though their response was much reduced
when compared to 6.5+ naive cells. Curiously, contrary to
6.5+ cells from single TCR transgenic mice, the recovered
cells proliferated better upon stimulation with the 6.5+
mAb than upon stimulation with the peptide. At 6 or 8 d
after transfer, the remaining 6.5+ cells gave an even lower
response than on day 4 to either the peptide or the clonotypic antibody (Table 1) and their anergic state could not
be reversed by exogenous IL-2. Cells recovered from HA+
recipients at day 4 after transfer were still capable of expanding in vivo when retransferred into another HA+ recipient, while cells recovered 21 d after transfer were no longer capable of doing so (data not shown). Cytokine production by the 6.5+ cells recovered at different timepoints
after transfer into antigen-positive recipients was also studied: IFN-
and IL-4 were produced at significant levels
when cells were stimulated in vitro at early timepoints after
transfer. At day 30 after transfer, no proliferation and no
IFN-
secretion by remaining cells could be detected (data not shown).
These data thus indicate that class II restricted mature T cells can undergo deletion or become anergic when exposed to high doses of antigen for longer timepoints. We next determined whether any of the classical protocols of inducing tolerance would induce a similarly unresponsive state of 6.5+ cells in situ.
Single Doses of Antigen Applied by Different Routes Do Not Induce Tolerance.Single doses of oral administration of either high or low doses of antigen were reported to induce
tolerance by deletion and anergy, respectively (19, 20, 21).
We therefore fed 6.5+ mice with high (1 mg of peptide) or
with low (0.1 mg of HA-Ig) doses of antigen in order to assess the effects of oral feeding on the 6.5 cells. We used low
doses of HA-Ig rather than peptide since in the original
protocols protein antigen rather than peptides were used.
The fed mice were analyzed at different timepoints and
numbers of antigen-specific cells as well as their proliferative capacity and cytokine secretion were studied. Feeding
with both high and low doses of antigen decreased cell
numbers in thymus and periphery to a certain extent (to
one half), indicating that the orally administered antigen
reached the antigen-specific T cells. Nevertheless, no significant effect on cell proliferation or cytokine release could
be observed at any timepoint analyzed. It has also been described that oral feeding of antigen shifts the cytokine production pattern among the antigen specific cells towards
IL-4, TGF-, and IL-10 production (12). However, we observed no decrease in IFN-
production and did not detect significant IL-4 production by 6.5+ cells from orally
fed mice when stimulated with antigen in vitro. The ELISA
system that was used can reproducibly detect up to 150 pg/
ml of IL-4 meaning that any shift towards IL4 production
was below that level.
Also administration of soluble antigen given intravenously or intraperitoneally has been reported to induce antigen-specific tolerance (8, 10, 22, 23). We analyzed therefore the effect of the similar doses of antigen given by these routes. Since the injection of 1 mg of peptide was reproducibly lethal at 20-24 h after injection (the same quantity of peptide injected into non-transgenic mice had no such effect), we used 0.75 mg of peptide as the highest dose and 0.1 mg of HA-Ig as a lower dose of antigen. Again, we analyzed the numbers of 6.5+ cells, as well as their capacity to proliferate and to produce cytokines. The data shown are for lymph nodes and were similar with spleen cells. Administration of both peptide at high doses and HA-Ig at low doses had a marked effect on numbers of 6.5+ thymocytes at day 3 and on peripheral 6.5+ cells at day 6 after injection (data not shown). The in vitro proliferative response of the antigen-specific cells at day 6 after injection was reduced by one half but this was due in most part to the lower percentage of 6.5+ cells per well. Thus, the functional capacity of the remaining 6.5+ cells was not significantly affected even 6 d after antigen administration, at a point in time when the number of peripheral antigen-specific cells was decreased the most.
We also injected 6.5+ mice with a single dose (0.1 mg) of deaggregated HA-Ig since it was reported that a single injection of deaggregated Ig could induce long lasting unresponsiveness (9). In the transgenic mice, however, such protocol had no measurable effect.
Responsiveness Is Reduced More Efficiently by HA-Ig than by Peptide when Given Repeatedly.Because it had been demonstrated that tolerance induction in CD8+ cells is dependent on antigen persistence (24, 25), we injected 6.5+ mice
i.v. with 0.1 mg of HA-Ig or peptide five times every other day and analyzed them 6 days after the last injection. The
numbers of 6.5+ cells in the thymus and periphery are
shown in Fig. 4 and were markedly decreased in the thymus and in the lymph nodes of treated animals. The decrease in lymph nodes was antigen-specific because the
proportion of 6.5+ cells among CD4+ and CD8+ cells was
likewise decreased. Despite the fact that, in terms of molarity, 0.1 mg of the peptide represents at least 2 × 104 more
peptide molecules than 0.1 mg of the HA-Ig, no difference was observed in their capacity to induce partial deletion or
to decrease the proliferative response of antigen-specific
cells. This could mean that peptide may be very rapidly
cleared upon injection when compared with proteins. Furthermore, the fact that the proteic antigen that contains the
peptide sequence has an Ig-Fc part may facilitate its uptake
and presentation by Fc receptor-bearing APCs. For these
reasons, in all protocols tested hereafter we used the HA-Ig
and not the peptide as source of soluble antigen.
In spite of the prolonged presence of antigen, the remaining antigen-specific cells in the periphery were still responsive to antigenic stimulation in vitro (Fig. 4 c). In addition, mice treated with the HA-Ig had very big spleens that contained higher numbers of 6.5+ cells when compared to the control mice or peptide-treated mice. This represents certainly an undesired effect of protocols aiming to induce tolerance in mature T cells.
The Combination of CD4 Antibodies and HA-Ig Can Induce a Transient State of Unresponsiveness.It has been shown by
several groups that administration of CD4 and/or CD8 antibodies can be helpful in the establishment of peripheral
tolerance (26, 27, for review see reference 28). Again, the
precise mechanisms are not known. To study the effect of
CD4 antibodies on responsiveness to HA we adopted a
protocol described by Bushell et al. (29) with the aim of (a)
decreasing CD4 cell numbers and (b) potentially providing
negative signals that may favor the induction of unresponsiveness. The CD4 antibody (YTA3.1.2) depleted 60-70%
of peripheral CD4 cells at day 7, as previously described
(18, 29). Mice were injected i.v. with 50 µg of the antibody YTA3.1.2 and 1 d later with 50 µg of YTA3.1.2 plus
0.1 mg of HA-Ig. Control mice received either only antigen or only CD4 antibody. Mice were killed at days 3, 7, and 14 and the number and functional capacity of the 6.5+
cells was determined. As can be seen in Fig. 5, combining
anti-CD4 and antigen considerably decreased cell numbers
and induced non-responsiveness in terms of proliferation as
well as of IFN- production when analyzed 7 d later. At
day 14, the cells began to regain responsiveness. This could
have been due to the fact that newly produced 6.5 cells, which had not been in contact with antigen, were entering
secondary lymphoid tissues from the thymus. This seemed,
however, not to be the case since 6.5+ cells from mice
thymectomized before treatment and analyzed 21 d after
treatment also recovered responsiveness. Therefore, the protocol proved to be efficient in induction, but not in
maintenance of tolerance. It is also clear that anti-CD4 on
its own had an effect on the proliferative capacity of 6.5+
cells, suggesting that part of this anergy at that point in time was not antigen specific. No effect of anti-CD4 alone was
observed in terms of IFN-
production, however, suggesting that the decrease in cytokine production observed at
day 7 in anti-CD4 plus antigen treated mice depended on
antigen. Such a decrease in IFN-
was not due to a Th1 to
Th2 shift among the antigen-specific cells since no IL4
production was detected. The lack of an effect of anti-CD4
on IFN-
production and the decreased IFN-
production after anti-CD4 plus antigen may be due to the fact that antigen is required to stop IFN-
production by the TCR
expressing CD8+ T cells.
The Administration of Anti-CD4/HA-Ig Followed by Repeated Antigen Administration Can Induce a Long-lasting Antigen-specific Tolerance.
Since the above protocol was efficient in inducing unresponsiveness but not in maintaining
it, we reasoned that administering antigen after such treatment in a manner that would favor its persistence could
help to maintain the tolerant state and would render the
treatment more antigen-specific. Therefore, mice treated 7 d earlier with anti-CD4 plus 0.1 mg of HA-Ig received
further injections of antigen. Different doses of HA-Ig
(ranging from 50 to 500 µg) were injected seven days after
treatment with CD4 antibody and 0.1 mg HA-Ig in 3-d
intervals. All mice were analyzed 7 d after the last injection
of antigen. As show in Fig. 6 there was a further reduction
in number of 6.5 cells in an antigen-dose dependent manner in mice that received antigen in addition to the initial
CD4 treatment. Significantly lowering the numbers of
CD4+ cells by the CD4 antibody avoided the splenomegaly that was otherwise seen with repeated doses of HA-Ig.
Likewise, the proliferative capacity of CD4+ cells to HA
was reduced in a dose-dependent manner and this reduction lasted for long periods of time (30 d) in thymectomized mice (data not shown). There was an increase in the
proportion of 6.5+CD69+ and of 6.5+ CD62-L cells that
correlated with antigen doses (Fig. 7). The 6.5+ cells recovered from the mice that repeatedly received either 0.5 or 0.1 mg of HA-Ig secreted very low levels of IFN-
(less than one-tenth of what was produced by the control mice)
and produced no IL4 (data not shown). It is interesting to
note that while IL4 production was detected after transfer
of 6.5 cells into antigen-bearing recipients (Table 1), it
could not be detected after any of the protocols aiming at
tolerance induction in situ. This difference may be due to
the fact that, upon transfer into antigen-containing recipients, cells were exposed to much larger doses of antigen and for a longer period of time.
This study was initiated with the aim to analyze the effect of various protocols that have previously been used to
induce tolerance on CD4+ HA-specific T cells with a
transgenic TCR that can be recognized by a monoclonal
antibody. In initial studies, HA antigen was expressed as a
self antigen in the hemopoietic system in HA+6.5+ double
transgenic mice. 6.5+ mature thymocytes were greatly diminished presumably because of the deletion of immature
thymocytes. The compartment of CD4+8+ cells was however not significantly affected much like it has been observed with superantigen (30) or with TCR transgenic mice specific for the C5 protein (31). In fact, CD4+CD8+
cells expressing higher levels of the transgenic TCR that
were present in HA6.5+ mice were absent in 6.5+HA+
mice (Fig. 1). Surprisingly however, there were a few cells
with the transgenic TCR in the lymph nodes of HA+6.5+
double transgenic mice and a highly significant number was
found in the spleen of these mice. These cells showed signs
of activation but could not be induced by either antigen or
receptor antibody to proliferate in vitro even in the presence of exogenous IL2. These cells may represent migrants
from the thymus that escaped deletion there and were anergized in secondary lymphoid organs. The function of
these cells differs from that of CD8lo cells that were detected in the spleen of mice with a class I MHC-restricted
TCR (2, 32) by the fact that these CD4+ cells could not be
activated by receptor antibodies. The existence of these autoreactive but anergic T cells is of interest and their origin
and migration needs to be addressed in future studies. In
this context it is worthwhile pointing out that in a recent study, autoreactive T cells were likewise detected in the
periphery of TCR transgenic mice with a class II MHC-
restricted TCR and were causing arthritis in those mice
(33). In the 6.5+ HA+ mice we have, however, not seen
any obvious signs of disease.
When mature HA-specific T cells encountered the HA
antigen expressed by hemopoietic cells for the first time after transfer from 6.5+ mice into HA+ recipients, they behaved much like mature CD8+ T cells that were similarly
exposed to a class I MHC-presented antigen: after an initial
phase of rapid expansion, cells were deleted and the remainder became anergic. The induction of unresponsiveness in terms of proliferation and IFN- production took
several days.
The experiments with mice that express HA-antigen on hemopoietic cells are relevant with regard to self tolerance and the transfer experiments with regard to graft versus host disease for instance after transplantation of allogeneic bone marrow that contains mature T cells. It would appear that in the latter case T cells specific for antigens that are ubiquitously expressed on hemopoietic cells become tolerant much like the CD4+ cells with the transgenic TCR when transferred into HA+ recipients, and thus one might expect that cells which cause late or chronic graft versus host disease are directed against different antigens. On the other hand, the depletion of hemopoietic cells before bone marrow transplantation may interfere with the tolerization process that is observed in our experiments.
The experiments in mice expressing HA on hemopoietic cells are obviously of limited relevance for procedures that aim at the tolerization of T cells in situ with the goal to prevent or interfere with graft rejection, autoimmunity or allergy. We therefore tried to develop procedures that would reliably interfere with the response of a relatively high frequency of T cells roughly equivalent to that of cells responding to a foreign MHC haplotype. It may be primarily for this reason that the traditional experimental protocols that were often but not always successful in establishing tolerance to non-MHC antigens failed here. Whether this is solely due to the relatively high frequency of antigen-specific T cells or to the absence of regulatory T cells in our TCR transgenic mice is not known. It should, however, be noted that in our mice the majority of CD4+ and CD8+ T cells do not express the transgenic TCR. One would assume that some of these cells are autoreactive, and thus, if regulatory T cells have an important role in self tolerance they would have to be operative in these TCR transgenic mice. One may wonder why tolerization failed even when repeated doses of antigen were given. This could be due to the fact that cells once exposed to antigen in a dose insufficient to delete become more resistant to antigen-mediated deletion. Whatever the reason for the failure of these traditional protocols, we noted that decreasing the number of antigen-specific T cells by reducing the total number of CD4+ T cells by CD4 antibodies was helpful. It was under these conditions that the addition of antigen caused unresponsiveness that could be maintained for long periods of time if antigen was given repeatedly. Although we cannot rule out any negative signal delivered by the CD4 antibodies, the data are certainly consistent with the notion that the frequency of reactive T cells and the dose and persistence of antigen are an important parameter determining tolerance. This would be in agreement with a study by Kearney et al. (15) where tolerance induction of cells expressing a class II-restricted transgenic TCR was only achieved after transfer of a small quantity of such cells into syngeneic non-transgenic recipients even though it is not clear what influence the transfer procedure had on these cells. Similarly, a study of Förster et al. (34) indicated that the ratio of the number of responsive T cells over the amount of antigen represented a crucial parameter in tolerance induction although in their study the antigen may have been expressed in the thymus.
It is interesting to note that with none of the employed
protocols, be it peptide injection or injection of soluble and
deaggregated protein, feeding of antigen, or giving the antigen together with CD4 antibodies, did we observe either
a complete deletion of antigen specific T cells or a qualitative change in the lymphokine secretion profile of the remaining cells in terms of shift from IFN- secretion to the
production of IL4 as suggested by Zhang et al. (35). So far
we have consistently only been successful with one type of
tolerization protocol, namely shifting the balance between the frequency of reactive T cells and the dose of antigen in
favor of the latter and observing deletion of cells as well as
induction of anergy.
Address correspondence to Adelaida Sarukhan, Unité INSERM 373, Institut Necker, 156 Rue de Vaugirard, 75730 Paris Cedex 15.
Received for publication 17 September 1996
This work was supported by funds from the Institut National de la Santé et de la Recherche Médicale. H. von Boehmer is supported by the Human Frontier Science Program.We thank B. Rocha for helpful advice.
1. | Webb, S., C. Morris, and J. Sprent. 1990. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63: 1249-1256 [Medline] . |
2. | Rocha, B., and H. von Boehmer. 1991. Peripheral selection of the T cell repertoire. Science (Wash DC) 251: 1225-1227 [Medline] . |
3. | Rammensee, H.R., R. Kroschewski, and B. Frangoulis. 1989. Clonal anergy induced in mature Vb6+ T lymphocytes on immunizing Mls-1b with Mls-1a expressing cells. Nature (Lond) 339: 541-543 [Medline] . |
4. | Kawabe, Y., and A. Ochi. 1990. Selective anergy of Vb8+ CD4+ cells in staphylococcus enterotoxin B-primed mice. J. Exp. Med 172: 1069-1078 . |
5. | Schonrich, G., U. Kalinke, F. Momburg, M. Malissen, A.M. Schmitt-Verhulst, B. Malissen, G.J. Hammerling, and B. Arnold. 1991. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell. 65: 293-310 [Medline] . |
6. | Gershon, R.K.. 1975. A disquisition on suppressor T cells. Transplant. Rev 26: 170-185 [Medline] . |
7. | Qin, S., S.P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, and H. Waldmann. 1993. Infectious transplantation tolerance. Science (Wash DC). 259: 974-976 [Medline] . |
8. | Chiller, J.M., G.S. Habicht, and W.O. Wiegle. 1971. Kinetic differences in unresponsiveness of thymus and bone marrow cells. Science (Wash DC). 171: 813-815 [Medline] . |
9. | Romball, C.G., and W.O. Weigle. 1993. In vivo induction of tolerance in murine CD4+ cell subsets. J. Exp. Med 178: 1637-1644 [Abstract] . |
10. |
Mondino, A.,
A. Khoruts, and
M.K. Jenkins.
1996.
The
anatomy of T-cell activation and tolerance.
Proc. Natl. Acad.
Sci. USA
93:
2245-2252
|
11. | Wells, H.. 1911. Studies on the chemistry of anaphylaxis. III. Experiments with isolated proteins, especially those of the hen's egg. J. Infect. Dis. 9: 147-151 . |
12. | Weiner, H.L., A. Friedman, A. Miller, S.J. Khoury, A. AlSabbagh, L. Santos, M. Sayegh, R.B. Nussenblatt, D.E. Trenthan, and D.A. Hafler. 1994. Oral tolerance: immunologic mechanisms and treatment of animal and human organ specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol 12: 809-837 [Medline] . |
13. | Rocha, B., A. Grandien, and A. Freitas. 1995. Anergy and exhaustion are independent mechanisms of peripheral tolerance. J . Exp. Med. 181: 993-1003 [Abstract] . |
14. | MacDonald, H.R., S. Baschieri, and R.K. Lees. 1991. Clonal expansion precedes anergy and death of V beta 8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur. J. Immunol 21: 1963-1966 [Medline] . |
15. | Kearney, E.R., K.A. Pape, D.Y. Loh, and M.K. Jenkins. 1994. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity. 1: 327-339 [Medline] . |
16. | Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, and H. von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180: 25-34 [Abstract] . |
17. | Zaghouani, H., R. Steinman, R. Nonacs, H. Shah, W. Gerhard, and C. Bona. 1993. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science (Wash DC) 259: 224-227 [Medline] . |
18. | Qin, S., S. Cobbold, H. Tighe, R. Benjamin, and H. Waldmann. 1987. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur. J. Immunol. 17: 1159-1165 [Medline] . |
19. |
Whitacre, C.C.,
I.E. Gienapp,
C.G. Orosz, and
D.M. Bitar.
1991.
Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy.
J. Immunol
147:
2155-2163
|
20. | Chen, Y., V.K. Kuchroo, J. Inobe, D.A. Hafler, and H.L. Weiner. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Nature (Lond). 265: 1237-1240 . |
21. | Chen, Y., J. Inobe, R. Marks, P. Gonnella, V. Kuchroo, and H.L. Weiner. 1995. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature (Lond) 376: 177-180 [Medline] . |
22. | Dresser, D.W.. 1961. Efectiveness of lipid and lipidophilic substances as adjuvants. Nature (Lond) 191: 1169-1171 [Medline] . |
23. | Mitchison, N.A.. 1964. Proc. Roy. Soc. 161: 275-290 . |
24. | Ramsdell, F., and B.J. Fowlkes. 1992. Maintenance of in vivo tolerance by persistance of antigen. Science (Wash DC). 257: 1130-1132 [Medline] . |
25. | Rocha, B., C. Tanchot, and H. von Boehmer. 1993. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J. Exp. Med. 177: 1517-1521 [Abstract] . |
26. | Qin, S., S. Cobbold, R. Benjamin, and H. Waldmann. 1989. Induction of classical transplantation tolerance in the adult. J. Exp. Med. 169: 779-794 [Abstract] . |
27. | Wood, K.J.. 1990. Transplantation tolerance with monoclonal antibodies. Semin. Immunol 2: 389-399 [Medline] . |
28. | Cobbold, S.P., S. Qin, L.Y. Leong, G. Martin, and H. Waldmann. 1992. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol. Rev. 129: 165-201 [Medline] . |
29. | Bushell, A., P.J. Morris, and K.J. Wood. 1995. Transplantation tolerance induced by antigen pretreatment and depleting anti-CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response. Eur. J. Immunol. 25: 2643-2649 [Medline] . |
30. | Kappler, J.W., N. Roehm, and P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell. 49: 273-280 [Medline] . |
31. | Zal, T., A. Volkmann, and B. Stockinger. 1994. Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J.Exp. Med. 180: 2089-2099 [Abstract] . |
32. | Kisielow, P., H. Bluthmann, U.D. Staerz, M. Steinmetz, and H. von Boehmer. 1988. Tolerance in T cell receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature (Lond) 333: 742-746 [Medline] . |
33. | Kouskoff, V., A.S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis. 1996. Organ-specific disease provoked by systemic autoreactivity. Cell. 87: 811-822 [Medline] . |
34. | Förster, I., R. Hirose, J.M. Arbeit, B.E. Clausen, and D. Hanahan. 1995. Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neoantigen. Immunity 2: 573-585 [Medline] . |
35. | Zhang, L., R.G. Miller, and J. Zhang. 1996. Characterization of apoptosis-resistant antigen-specific T cells in vivo. J. Exp. Med. 183: 2065-2073 [Abstract] . |